<DOC>
	<DOCNO>NCT00003409</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Motexafin gadolinium may increase effectiveness radiation therapy make tumor cell sensitive radiation . PURPOSE : Phase I trial study effectiveness motexafin gadolinium plus radiation therapy treat patient newly diagnose glioblastoma multiforme .</brief_summary>
	<brief_title>Motexafin Gadolinium Plus Radiation Therapy Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety tolerability motexafin gadolinium combination radiotherapy patient newly diagnose glioblastoma multiforme . II . Determine intratumoral pharmacology quantitative pharmacokinetics drug patient population . OUTLINE : This multicenter , dose-escalation study motexafin gadolinium . Patients receive load dose regimen comprise motexafin gadolinium IV 10-15 minute day 1-5 day 1-5 8-12 ( cohort 7 ) . After load dose regimen , patient receive maintenance regimen comprise motexafin gadolinium IV 3 time weekly maximum 6.5 week . Patients also undergo radiotherapy daily , 5 day week , 6.5 week . Cohorts 3-6 patient receive escalate number dos motexafin gadolinium maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Patients follow 4 week every 3 month thereafter . PROJECTED ACCRUAL : A maximum 35 patient accrue study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose glioblastoma multiforme require radical radiotherapy No anaplastic astrocytoma lowgrade astrocytoma Able start radiotherapy within 5 week definitive surgery ( unless delay due cause medical illness poor performance status ) PATIENT CHARACTERISTICS : Age : 18 Performance status : See Disease Characteristics Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : AST ALT great 2 time upper limit normal ( ULN ) Bilirubin great 2 mg/dL PT aPTT great 1.5 time ULN Renal : Creatinine le 1.5 mg/dL Cardiovascular : No severe cardiac disease Pulmonary : No severe lung disease Other : No significant lifethreatening disease No active malignancy No known glucose6phosphate dehydrogenase deficiency No know porphyria Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No biologic therapy least 4 week study completion No immunotherapy least 4 week study completion Chemotherapy : No chemotherapy least 4 week study completion Endocrine therapy : Concurrent steroid allow Radiotherapy : See Disease Characteristics No prior radiotherapy disease brain tumor No prior radiotherapy face , head , neck Surgery : See Disease Characteristics Recovered prior surgery postoperative complication Other : At least 48 hour since prior MRI scan contrast No concurrent MRI scan contrast No concurrent experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>